Services
Company
Legal and Governance
Insights / Whitepapers
Smarter SLRs or Risky Shortcuts? Perspectives From Global HTA Stakeholders
Written by Grace E. Fox, Juliette Torres Ames, Nita Santpurkar, Jed Avissar, and Emanuele Arcà on Monday, July 28, 2025
As a follow up to our recent ISPOR-sponsored webinar, this whitepaper explores a critical and timely question in health technology assessment:
How do HTA agencies view the integration of AI into SLRs?
Given the growing demand for faster, more efficient evidence synthesis, the use of AI holds clear promise. But that promise comes with a caveat—HTA agencies are proceeding cautiously.
Read our whitepaper for updated findings on current guidance from HTA agencies on AI use, along with real-world perspectives from HTA stakeholders.
Key highlights include:
- Only three agencies, CDA‑AMC (Canada), NICE (UK), and IQWiG (Germany), currently issue any specific recommendations on using AI in SLRs, each highlighting transparency and the necessity of human oversight
- Surveyed HTA professionals cited efficiency as AI’s primary advantage in SLRs, yet remained skeptical about its ability to reduce bias, emphasizing the importance of transparency and reproducibility
At OPEN Health, we connect visionary minds, pioneering science, and advanced technology to drive real impact. By uniting people, science, and technology, we activate new opportunities for biopharma innovation. Our expertise across medical affairs and market access unlocks faster, smarter routes to market. We are committed to improving patient outcomes worldwide.
OPEN Health. The right combination to unlock possibilities.
For information about OPEN Health’s services and how we could support you, please get in touch.